Stem Cell Secretome for the Treatment of Erectile Dysfunction
Stem cell therapy for erectile dysfunction has become an active area of scientific research. This article summarizes what published research has reported so far, explains the scientific rationale behind the stem cell secretome, and describes the treatment approach ANOVA applies at its clinic in Germany.
What is Erectile Dysfunction?
Erectile dysfunction (ED) is defined as the consistent or current inability to achieve and/or maintain an erection sufficient for satisfactory sexual performance.
ED is highly prevalent; its rates range from 10 to 50% for men of 40 to 70 years of age1. Risk factors for ED include hypertension, hyperlipidemia, diabetes, smoking, obesity, ß-blockers, anti-depressants, and alcohol use, amongst others2.
There are many different causes that can lead to ED. We published an article on the causes of ED previously.
Pharmacologically approved treatments for ED generally address the symptoms rather than the underlying cause of ED1, and a proportion of patients do not respond adequately to them3. This has motivated scientific interest in approaches that aim at the underlying tissue and vascular changes.
Results of Clinical Studies on Stem Cell Therapy for Erectile Dysfunction
More than forty preclinical (animal-model) studies have reported beneficial effects of bone marrow- and adipose-derived stem cells in nerve-injury-, aging- and diabetes mellitus-related ED3.
Early clinical studies in patients have since reported encouraging findings1: improvements in penile hardness in men with type 2 diabetes mellitus-related ED, the ability to achieve intercourse together with better IIEF-5 scores in continent patients after radical prostatectomy, and increases in penile artery peak systolic velocity. IIEF-5 stands for International Index of Erectile Function and is a standard questionnaire that tracks sexual function in men. Changes in the Erection Hardness Score (EHS) were also reported, with or without the concomitant use of PDE-5 inhibitors. These early clinical findings come from small studies and require further evaluation, but together with the preclinical data they provide a scientific rationale for the approach.
How stem cells produce these effects is not yet fully established. Current evidence suggests that they act largely through a local paracrine mechanism — that is, through the factors they secrete rather than through the cells themselves1. This observation is central to the rationale for secretome-based approaches.
Application and Treatment Frequency
In one clinical study, an initial improvement declined over time, which suggests that repeated applications may be needed to maintain an effect1. Informed by these findings, ANOVA uses a treatment scheme of repeated applications — where appropriate, in series of three to five applications repeated every few months.
How ANOVA Applies Secretome Therapy in ED
ANOVA applies secretome therapy in selected patients following an individual medical assessment. A typical scheme combines intravenous and intracavernous applications of Mesenchymal stem cell (MSC) Secretome.
For example, a total of 5 intravenous and 5 intracavernous applications may be given in two treatment blocks a few months apart, each block delivered over the course of three days, as shown in the figure.

Figure 1: Example of a treatment scheme used in erectile dysfunction.
In ANOVA's clinical experience, some patients have reported changes in sexual function following treatment. Individual experiences of this kind vary from person to person and are not a substitute for controlled clinical data, but they are broadly consistent with the findings reported in the scientific literature.
What is the ANOVA IRM secretome?
The secretome provided by ANOVA IRM contains exosomes and other soluble factors secreted by mesenchymal stem cells, and it is cell-free. A single donation of the patient's own — so-called autologous — mesenchymal stem cells, obtained from abdominal fat, is enough to isolate and briefly cultivate the cells under mild laboratory conditions. The cells are then separated from the conditioned medium, which contains the secreted exosomes and soluble factors. The resulting personalized secretome undergoes pharmaceutical quality control and can be used for up to 10 treatments, scheduled according to the patient's individual situation. Manufacturing takes place within the German pharmaceutical regulatory framework and under the supervision of the competent German drug authorities.
Rationale for a Cell-Free Approach
Because the secretome is cell-free, this approach might offer advantages over the administration of living cells: it avoids certain risks associated with cell transplantation, and the brief, mild cultivation is intended to preserve the activity of the secreted factors. Since paracrine signalling appears central to the effect, delivering the secreted factors directly is a scientifically reasonable strategy. The personalized secretome can be stored and used across several sessions, which fits the observation that stem-cell-based approaches are generally not one-time treatments but part of an ongoing plan.
Whether Stem Cell Secretome may be an option depends on the individual's current health status and the underlying problem in each specific case. ANOVA's physicians review each person's medical files and discuss whether treatment may be considered.
Stem-cell-based and secretome therapies remain developing medical approaches. The available evidence varies by indication, individual outcomes cannot be predicted, and treatment is offered only following an individual medical assessment.
References and Literature - Stem Cell Secretome for the treatment of ED
- Capogrosso, Paolo, Francesco Montorsi, and Andrea Salonia. "Phase I and phase II clinical trials for the treatment of male sexual dysfunction—a systematic review of the literature." Expert Opinion on Investigational Drugs 27.7 (2018): 583-593.
- Haahr, Martha Kirstine, et al. "Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial." EBioMedicine 5 (2016): 204-210.
- Gómez-Guerra, Lauro S., et al. "Erectile dysfunction treated with intracavernous stem cells: A promising new therapy?." Revista internacional de andrologia 16.3 (2018): 119-127.
News & Insights
Patient Services at ANOVA Institute for Regenerative Medicine
- Located in the center of Germany, quick access by car or train from anywhere in Europe
- Simple access worldwide, less than 20 minutes from Frankfurt Airport
- Individualized therapy with state-of-the-art autologous stem cell products
- Individually planned diagnostic work-up which include world-class MRI and CT scans
- German high quality standard on safety and quality assurance
- Personal service with friendly, dedicated Patient Care Managers
- Continuous analysis of scientific data in the field of regenerative medicine